Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial
Journal of Stroke · 31.05.2023 · 25 (2) · 242-250
DOI: 10.5853/jos.2022.02957 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Stroke, erschienen am 31.05.2023. Verfasst von Keun-Sik Hong und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Ilsan Paik Hospital, Inje University, Goyang, Korea. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hanmi Pharm. Co., Ltd.
Themen: Schlaganfall
Abstract (Originalsprache)
Background and Purpose Moderate-intensity statin plus ezetimibe versus high-intensity statin alone may provide a greater low-density lipoprotein cholesterol (LDL-C) reduction in patients with recent ischemic stroke.Methods This randomized, open-label, controlled trial assigned patients with recent ischemic stroke
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Ilsan Paik Hospital, Inje University, Goyang, Korea.
- Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Neurology, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea.
- Department of Neurology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea.
- Department of Neurology, Seoul Hospital, Ewha Women's University College of Medicine, Seoul, Korea.
- Department of Neurology, Yonsei University College of Medicine, Seoul, Korea.
Förderung
- Hanmi Pharm. Co., Ltd
Zitieren
APA
Hong, K. S., Bang, O. Y., Park, J. H., Jung, J. M., Lee, S. H., Song, T. J., Nam, H. S., Park, H. K., Jung, K. H., Heo, S. H., Koo, J., Yu, K. H., Park, K. Y., Kim, C. K., Park, H. K., Lee, J., Lee, J., & Seo, W. K. (2023). Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial. Journal of Stroke, 25(2), 242-250. https://doi.org/10.5853/jos.2022.02957
Vancouver
Hong KS, Bang OY, Park JH, Jung JM, Lee SH, Song TJ, et al. Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial. Journal of Stroke. 2023;25(2):242-250. doi:10.5853/jos.2022.02957
BibTeX
@article{Hong2023,
author = {Hong, Keun-Sik and Bang, Oh Young and Park, Jong-Ho and Jung, Jin-Man and Lee, Sang-Hun and Song, Tae-Jin and Nam, Hyo Suk and Park, Hee-Kwon and Jung, Keun-Hwa and Heo, Sung Hyuk and Koo, Jaseong and Yu, Kyung-Ho and Park, Kwang-Yeol and Kim, Chi Kyung and Park, Hong-Kyun and Lee, Jiyoon and Lee, Juneyoung and Seo, Woo-Keun},
title = {Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial},
journal = {Journal of Stroke},
year = {2023},
volume = {25},
number = {2},
pages = {242--250},
doi = {10.5853/jos.2022.02957}
}
EUVIMED